Literature DB >> 21931334

Diencephalic and brainstem mechanisms in migraine.

Simon Akerman1, Philip R Holland, Peter J Goadsby.   

Abstract

Migraine is a common and complex brain disorder. Although it is clear that head pain is a key manifestation of the disorder for most patients, what drives the activation of neuronal pain pathways in susceptible patients is less obvious. There is growing evidence that migraine pathophysiology may, in part, include dysfunction of subcortical structures. These include diencephalic and brainstem nuclei that can modulate the perception of activation of the trigeminovascular system, which carries sensory information from the cranial vasculature to the brain. Dysfunction of these nuclei, and their connections to other key brain centres, may contribute to the cascade of events that results in other symptoms of migraine - such as light and sound sensitivity - thus providing a comprehensive explanation of the neurobiology of the disorder.

Entities:  

Mesh:

Year:  2011        PMID: 21931334     DOI: 10.1038/nrn3057

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  198 in total

1.  Perfusion weighted imaging during migraine: spontaneous visual aura and headache.

Authors:  M Sanchez del Rio; D Bakker; O Wu; R Agosti; D D Mitsikostas; L Ostergaard; W A Wells; B R Rosen; G Sorensen; M A Moskowitz; F M Cutrer
Journal:  Cephalalgia       Date:  1999-10       Impact factor: 6.292

2.  Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications.

Authors:  J Olesen
Journal:  Cerebrovasc Brain Metab Rev       Date:  1991

3.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

4.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

5.  Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious craniovascular stimulation and periaqueductal gray stimulation in the cat.

Authors:  Yolande E Knight; John D Classey; Michele P Lasalandra; Simon Akerman; Fernando Kowacs; Karen L Hoskin; Peter J Goadsby
Journal:  Brain Res       Date:  2005-05-31       Impact factor: 3.252

6.  Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Authors:  T W Ho; L K Mannix; X Fan; C Assaid; C Furtek; C J Jones; C R Lines; A M Rapoport
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

7.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

8.  Anatomy and physiology of a nociceptive modulatory system.

Authors:  H L Fields; M M Heinricher
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1985-02-19       Impact factor: 6.237

9.  Premonitory symptoms in migraine: an electronic diary study.

Authors:  N J Giffin; L Ruggiero; R B Lipton; S D Silberstein; J F Tvedskov; J Olesen; J Altman; P J Goadsby; A Macrae
Journal:  Neurology       Date:  2003-03-25       Impact factor: 9.910

10.  Bright light activates a trigeminal nociceptive pathway.

Authors:  Keiichiro Okamoto; Akimasa Tashiro; Zheng Chang; David A Bereiter
Journal:  Pain       Date:  2010-03-04       Impact factor: 7.926

View more
  149 in total

1.  Enhanced neuronal excitability in adult rat brainstem causes widespread repetitive brainstem depolarizations with cardiovascular consequences.

Authors:  Frank Richter; Reinhard Bauer; Andrea Ebersberger; Alfred Lehmenkühler; Hans-Georg Schaible
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-28       Impact factor: 6.200

2.  Decade in review-migraine: incredible progress for an era of better migraine care.

Authors:  Peter J Goadsby
Journal:  Nat Rev Neurol       Date:  2015-10-27       Impact factor: 42.937

3.  Brain disposition and catalepsy after intranasal delivery of loxapine: role of metabolism in PK/PD of intranasal CNS drugs.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

4.  Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and "triptan" receptors: implications in migraine.

Authors:  Simon Akerman; Philip R Holland; Michele P Lasalandra; Peter J Goadsby
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

5.  Non-Trigeminal Nociceptive Innervation of the Posterior Dura: Implications to Occipital Headache.

Authors:  Rodrigo Noseda; Agustin Melo-Carrillo; Rony-Reuven Nir; Andrew M Strassman; Rami Burstein
Journal:  J Neurosci       Date:  2019-01-08       Impact factor: 6.167

Review 6.  What the Gut Can Teach Us About Migraine.

Authors:  Nada Hindiyeh; Sheena K Aurora
Journal:  Curr Pain Headache Rep       Date:  2015-07

Review 7.  Update on animal models of migraine.

Authors:  Marcela Romero-Reyes; Simon Akerman
Journal:  Curr Pain Headache Rep       Date:  2014-11

Review 8.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 9.  Emerging therapies for chronic migraine.

Authors:  Alberto Proietti Cecchini; Licia Grazzi
Journal:  Curr Pain Headache Rep       Date:  2014-04

10.  Structural abnormalities in the thalamus of migraineurs with aura: a multiparametric study at 3 T.

Authors:  Cristina Granziera; Alessandro Daducci; David Romascano; Alexis Roche; Gunther Helms; Gunnar Krueger; Nouchine Hadjikhani
Journal:  Hum Brain Mapp       Date:  2013-03-01       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.